Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway.

Trial Profile

Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Bortezomib; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov
    • 15 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 18 Nov 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top